The insights gained from this study provide a solid foundation for developing targeted therapies that leverage the benefits of HO-1 up-regulation while mitigating its potential drawbacks, ultimately contributing to improved management of hypertension and ROS-related metabolic disorders. This evidence concerns the gene HMOX1 and Other metabolic disease.